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cGVHD. Interestingly, rapamycinpreventeddeath fromcGVHD
in that model, perhaps through in vivo expansion of Treg.419
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Graft-versus-host disease (GVHD) frequently causes
morbidity and mortality after allogeneic hematopoietic cell
transplantation (HCT). In HLA-identical HCT, GVHD results
from donor T cell recognition of minor histocompatibility (H)
antigens on recipient tissues. Complete T cell depletion (TCD)
of donor hematopoietic cell products is more effective than
pharmacologic immunosuppression for preventing GVHD,
but is complicated by delayed immune reconstitution and
consequent life-threatening infections. Approaches to HCT
that preferentially deplete T cells responsible for GVHD and
preserve pathogen-speciﬁc T cells may improve outcomes.
Mature CD3+CD8+ and CD3+CD4+ T cells can be classiﬁed into
CD45RA+CD62L+ naïve (TN) and CD45RO+ memory (TM)
subsets, the latter of which includes effector memory (TEM)
and central memory (TCM) T cells. Murine studies in MHC-
matched and emismatched models demonstrated that
transplanting TN cells causes severe GVHD, puriﬁed TCM
causes mild GVHD, and TEM do not cause GVHD. In vitro
studies have similarly demonstrated that human donor CD8+
T cells speciﬁc for recipient minor H antigens are found
predominantly within the TN cell subset. In sum, these data
suggest that selective TNcell depletion may alter the inci-
dence or severity of GVHD in human HCT.
We developed an effective process for engineering human
peripheral blood stem cell (PBSC) grafts that depletes
CD45RA+ TN and retains CD34+ stem cells and functional
CD45RO+ TM speciﬁc for diverse opportunistic pathogens.We
initiated a clinical trial to evaluate selective depletion of TN
cells from allogeneic PBSC for the prevention of GVHD in
patients with acute leukemia. Each of the ﬁrst 22 patients has
engrafted (median day 12), regimen-related toxicity has
been acceptable, T-cell numbers recover faster than reported
for TCD HCT (median 412 CD3+ T cells/ml on day 28), and
there is no increase in the rate of relapse, opportunistic
infections, or EBV reactivation compared to patients treated
with T cell replete PBSC grafts. Early onset gastrointestinal
symptoms that are compatible with mild acute GVHD occur
frequently, but rapidly respond to therapy, and most patients
have successfully tapered immunosuppression. T cell
responses to pathogens recover early after HCT. At a median
of 14 months follow-up, overall and disease free survival are
80% and 75% respectively, and the frequency and severity of
chronic GVHD is substantially reduced compared to recipi-
ents of T cell replete PBSC grafts.420
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Hospital), Utrecht, NetherlandsIntroduction: Acute graft versus host disease (aGvHD) is
a common (20-50% of all HSCT recipients) and potentially
lethal complication after allogeneic hematopoietic stem cell
transplantation (HSCT). Risk factors for aGvhD include donor
source, preparative regimen and the degree of HLA-mis-
matching. Currently, there is increasing evidence that
(reactivation of) viral infection is a risk factor for aGvHD. We
hypothesized that the presence of viruses in the gastroin-
testinal tract, including AdV, triggers the initiation phase of
intestinal GvHD. Therefore we investigated the association
between viral PCR-positivity in stool prior to HSCT and the
occurrence of intestinal aGvHD.
Methods: We prospectively evaluated 27 consecutive pedi-
atric allogeneic HSCT patients from January ’09 until October
’10. Primary endpoint was the development of intestinal
aGvHD diagnosed according to Gluckbergs criteria and
conﬁrmed by histopathology. Follow-up ranged from 100 to
376 days or until death. Stool specimens were taken peri-
HSCT and analyzed for entero-, -noro-, astro-, -parecho- and
adenovirus, by real-time PCR. The association between fecal
PCR- positivity and intestinal aGvHD was analyzed using
Fisher's exact tests.
Results: Of the 27 patients that were evaluated, 6 (22%)
developed intestinal aGvHD after a median of 64 days (range,
38-74). Four (15%) patients died due to transplant related
complications or disease progression/relapse after 22-61
days. All patients with stool specimens positive for AdV (4/
27, 15%) developed intestinal aGvHD (versus 2 / 23 (9%)
patients without AdV in stool,P ¼ .001, positive predictive
value¼ 100%, negative predictive value¼ 91%). Four patients
were positive for other viruses but none of these developed
aGvHD. Interestingly, one patient became positive for AdV at
327 days post-SCT and developed chronic intestinal GvHD
after 476 days. AdV persisted in patient stool for more than
140 days, and preceded systemic infection: AdV was ﬁrst
detected in plasma on day 409 and loads raised from 482
copies/ml to 1.4*10.4 copies/ml on day 500.
Conclusion: AdV in stool prior to HSCT was associated with
intestinal acute GvHD. It supports the hypothesis that virally
induced tissue damage leads to inﬂux of inﬂammatory
mediators and ultimately activation and inﬂux of activated
cytotoxic T-cells involved in GvhD. Currently we perform
a prospective follow- up study. These results may impact
monitoring and treatment (preventive and curative) guide-
line/protocols.421
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Recent research has increased our understanding of
lymphocyte metabolism in vitro, but the metabolism of
lymphocytes activated in vivo remains poorly understood. To
evaluate this important issue further, we explored the
metabolism of proliferating, donor T lymphocytes seven days
after the initiation of graft versus-host disease (GVHD) in an
acute model of GVHD (B6 into B6D2F1). Donor T cells up-
regulated mRNA for fatty acid (FA) transport proteins (e.g.
